L'IA può prevedere la risposta di un paziente a un antidepressivo entro 48 ore dalla prima dose ?

Gli strumenti di intelligenza artificiale che utilizzano la variabilità della frequenza cardiaca, la dilatazione della pupilla o gli stati micro di EEG per prevedere l'efficacia degli antidepressivi entro due giorni spingono al limite la sensibilità dei biomarcatori e l'inferenza causale. La pratica clinica attuale si basa sull'osservazione di trial che durano settimane. La validazione richiede trial in cieco con esiti clinici di riferimento e soglie statistiche rigorose.

Background

Researchers have explored AI tools using heart rate variability, pupil dilation, or EEG microstates to forecast antidepressant efficacy within two days, pushing the limits of biomarker sensitivity and causal inference. Current clinical practice relies on weeks-long trial observation. Validation requires blinded trials with ground-truth clinical outcomes and rigorous statistical thresholds. A 2020 review in the Journal of Clinical Psychopharmacology noted that while AI has shown promise in analyzing large datasets—including genetic information, brain imaging, and clinical variables—the ability to predict response within 48 hours remains in the early stages. Biomarkers tied to changes in brain activity or gene expression have been investigated, yet these findings are preliminary, and more research is needed to develop reliable predictive models. Clinicians still largely depend on trial and error and patient-reported outcomes to assess antidepressant effectiveness. As of May 14, 2026, predicting antidepressant response within 48 hours of the first dose remains an active area of investigation.